MRNA vs RVTY
Moderna vs Revvity — AI-powered side-by-side comparison
| Metric | MRNA | RVTY |
|---|
| AI Score |
61
|
71
|
| Price |
$158.81
|
$124.78
|
| P/E Ratio |
-17.40×
|
58.57×
|
| ROE |
-32.6%
|
3.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
-12.6%
|
52.1%
|
| Debt / Equity |
0.19×
|
0.46×
|
| Dividend Yield |
0.0%
|
0.2%
|
| RSI (14) |
68.6
|
67.0
|
| Beta |
0.899
|
1.072
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for MRNA versus RVTY.
RVTY leads by 10 points.
RVTY scores 71/100 (Buy) versus MRNA at 61/100 (Buy).
MRNA Committee View
67% agreement
6 analysts
The primary driver is price structure making higher highs and higher lows. The main limiting factor is bollinger bandwidth of 194.9% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.3x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- ROE of only -39.2% -- cheap may mean cheap for a reason — Value
- Revenue declining -27.6% YoY -- this is not a growth story right now — Growth
- Weekly RSI at 82 -- overbought on the larger timeframe too — Technical
RVTY Committee View
100% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is sector concentration is already high (hhi 3068.56). The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Stochastic RSI (91.1) confirms overbought conditions.
- Bearish candlestick pattern(s) detected: Bearish Engulfing.